Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This drug is a pentavalent combination vaccine designed for the active immunization of infants and toddlers against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and invasive infections caused by *Haemophilus influenzae* type b (Hib). The vaccine typically contains purified diphtheria and tetanus toxoids, acellular pertussis antigens (such as pertussis toxoid and filamentous hemagglutinin), inactivated poliovirus (types 1, 2, and 3), and the Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to a carrier protein, often tetanus toxoid. By combining these antigens into a single injection, the vaccine simplifies immunization schedules and improves compliance. Major commercial versions include Sanofi's Pentaxim and Pediacel, and GSK's Infanrix-IPV+Hib.
- Brand names
- PentaximPediacelPentavacInfanrix-IPV+Hib
- Other names
- DTaP-IPV-HibDTaP-IPV/HibDTacP-IPV//PRP~T
02
Targets
FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRN (Pertactin)Diphtheria toxinTT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine.